HEMOSHEAR, LLC

Basic Information

1115 5TH ST SW
CHARLOTTESVILLE, VA, 22902-6465

Company Profile

n/a

Additional Details

Field Value
DUNS: 809452217
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. IGF OT IGF SBIR PHASE II TOPIC TITLE VALIDATION OF THE HEMOSHEAR TUMOR MICROENVIRONMENT SYSTEM FOR DRUG DISCOVERY AND DEVELOPMENT

    Amount: $1,985,884.00

    Not Available

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  2. Development of a DIVI platform for issue resolution in pre-clinical drug development.

    Amount: $1,126,395.00

    DESCRIPTION provided by applicant Drug induced vascular injury DIVI is a common phenomenon in pre clinical animal studies and is typically characterized by hemorrhage vascular endothelial and sm ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  3. Development of an iPSC-derived human hepatocyte platform for drug development.

    Amount: $1,126,573.00

    DESCRIPTION provided by applicant Human inducible pluripotent stem cells iPSCs proliferate readily and can be terminally differentiated into hepatocytes which potentially makes them an attractiv ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  4. Development of an in vitro system of human hepatic steatosis.

    Amount: $255,128.00

    DESCRIPTION provided by applicant Non alcoholic fatty liver disease NAFLD is a rapidly emerging public health crisis affecting up to of Type diabetics and of obese individuals Glucose ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  5. Development of a human physiological multi-cellular liver platform for drug-induced liver injury and disease.

    Amount: $463,475.00

    DESCRIPTION provided by applicant Liver cell based systems are widely used to study drug metabolism toxicity and liver disease However the poor correlation between in vitro data and clinical out ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  6. Development of an iPSC-derived human vascular system for drug discovery and devel

    Amount: $249,013.00

    DESCRIPTION (provided by applicant): R43 SBIR: Development of an iPSC-derived human vascular system for drug development. ABSTRACT Human inducible pluripotent stem cells (iPSCs) can be differentiated ...

    SBIR Phase I 2014 Department of Health and Human Services
  7. Development of an iPSC-derived human hepatocyte platform for drug development.

    Amount: $281,942.00

    DESCRIPTION (provided by applicant): Human inducible pluripotent stem cells (iPSCs) proliferate readily and can be terminally differentiated into hepatocytes, which potentially makes them an attractiv ...

    SBIR Phase I 2014 Department of Health and Human Services
  8. Development of a human hepatocyte predictive pharmacology and toxicology system.

    Amount: $1,584,146.00

    DESCRIPTION (provided by applicant): There is a critical need to improve the accuracy of preclinical drug efficacy and toxicity screening and testing through the development of human hepatocyte (liver ...

    SBIR Phase II 2013 Department of Health and Human Services
  9. TOPIC 314: DEVELOPMENT OF HUMAN TISSUE CULTURE SYSTEM THAT MIMICS THE TUMOR MICRO

    Amount: $298,547.00

    Not Available

    SBIR Phase I 2013 Department of Health and Human Services
  10. Hemodynamic Co-Culture Liver Model for Drug Discovery and Assessment

    Amount: $190,786.00

    DESCRIPTION (provided by applicant): Drug developers desperately need better tools in the laboratory to improve the 90% failure rate of drugs in clinical trials. Liver toxicity is still the leading ca ...

    SBIR Phase I 2011 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government